Selected publications Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. Journal of Clinical Oncology. 2009 Academic Article GET IT Times cited: 248
